The aim of this study was to investigate the biological effects of belimumab on B cells in the first phase II open-label trial with belimumab in patients with primary SS (pSS) (BELISS).
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome
Fabris, Martina;QUARTUCCIO, Luca;CURCIO, Francesco;DE VITA, Salvatore
2015-01-01
Abstract
The aim of this study was to investigate the biological effects of belimumab on B cells in the first phase II open-label trial with belimumab in patients with primary SS (pSS) (BELISS).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
kev005.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non pubblico
Dimensione
231.64 kB
Formato
Adobe PDF
|
231.64 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
